| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.brawnbiotech.com | |
| Market Cap | 6.13 Cr. | |
| Enterprise Value(EV) | 5.84 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -4.13 | Trailing Twelve Months Ending 2023-09 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-09 |
| Industry PE | 41.03 | Trailing Twelve Months Ending 2023-09 |
| Book Value / Share | 19.03 | Trailing Twelve Months Ending 2023-09 |
| Price to Book Value | 1.07 | Calculated using Price: 20.44 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 0.30 Cr. | 3,000,300 Shares |
| FaceValue | 10 | |
| About Brawn Biotech Ltd. | ||
| Brawn Pharmaceuticals was incorporated in the year 1985 it operates in health care sector in India and outside India. It has started its business by selling pharmaceutical formulations manufactured by other company's loan license basis. The company is located in New Delhi, India. | ||
| 1 Day |
|
+4.98% |
| 1 Week |
|
+22.76% |
| 1 Month |
|
+8.09% |
| 3 Month |
|
+3.39% |
| 6 Month |
|
+3.60% |
| 1 Year |
|
+13.62% |
| 2 Year |
|
+8.15% |
| 5 Year |
|
-50.33% |
| 10 Year |
|
+296.12% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 5.91 | 18.15 | 22.39 | 17.62 | 16.37 | 6.6 | -6.1 | -20.53 | -12.83 | |
| Return on Capital Employed (%) | 11.98 | 26.39 | 29.04 | 27.75 | 23.03 | 9.74 | -3.57 | -25.66 | -5.94 | |
| Return on Assets (%) | 2.05 | 6.8 | 9.01 | 6.49 | 5.93 | 2.77 | -3.24 | -12.23 | -6.31 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 5 | 6 | 7 | 8 | 9 | 9 | 9 | 7 | 6 | 6 | |
| Non Curr. Liab. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Curr. Liab. | 9 | 8 | 10 | 15 | 14 | 11 | 5 | 6 | 8 | 5 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 14 | 14 | 17 | 22 | 22 | 20 | 14 | 13 | 14 | 12 | |
| Non Curr. Assets | 3 | 3 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | |
| Curr. Assets | 11 | 11 | 17 | 22 | 22 | 19 | 13 | 12 | 13 | 11 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 14 | 14 | 17 | 22 | 22 | 20 | 14 | 13 | 14 | 12 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09 Rs. Cr. TTM |
| Net Sales | 39 | 47 | 61 | 56 | 65 | 50 | 35 | 9 | 22 | 21 | |
| Other Income | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | ||
| Total Income | 39 | 47 | 61 | 56 | 66 | 50 | 35 | 9 | 22 | 21 | |
| Total Expenditure | -38 | -45 | -59 | -54 | -64 | -49 | -36 | -11 | -23 | -22 | |
| PBIDT | 1 | 1 | 2 | 2 | 2 | 1 | 0 | -2 | 0 | -1 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Taxation | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Exceptional Items | |||||||||||
| PAT | 0 | 1 | 1 | 1 | 1 | 1 | -1 | -2 | -1 | -1 | |
| Adjusted EPS | 1 | 3 | 5 | 4 | 4 | 2 | -2 | -5 | -3 | -4 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 0 | 0 | 0 | 1 | -2 | 0 | 0 | 0 | 0 | 0 | |
| Cash Fr. Inv. | 0 | 0 | 0 | 1 | 0 | 0 | 0 | ||||
| Cash Fr. Finan. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Net Change | 0 | 0 | 0 | 2 | -2 | 0 | 0 | 0 | 0 | ||
| Cash & Cash Eqvt | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 |
|
Fri, 12 Apr 2024
Compliances-Reg.24(A)-Annual Secretarial Compliance The requirement of filing Annual Secretarial Report is not applicable on the company as per Regulation 15(2) of SEBI(LODR) Regulations 2015. |
|||||||||||||||||||||
|
Thu, 11 Apr 2024
Compliance Certificate Under Regulation 7(3) Of SEBI (LODR) Regulations 2015. Compliance certificate under Regulation 7(3) of SEBI (LODR) Regulations 2015 for the period 1 April 2023 to 31 March 2024. |
|||||||||||||||||||||
|
Wed, 10 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No Name of the Company Secretary: Ms Priyanka Sharma Designation: Compliance Officer EmailId: solution@brawnbiotech.com Name of the Chief Financial Officer: Ms Pooja Pandey Designation: Chief Financial Officer EmailId: collections@brawnlabs.in Date: 10/04/2024 Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
| Tue, 23 Apr 2024 |
High Delivery Percentage
|
Opening at High
|
Opening at Low
|
Closing Above Previous High
|
Closing Above Previous High For 3 Days
|
